

Revision date: 27-Nov-2016

Version: 2.1

Page 1 of 8

# 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: BeneFIX

Trade Name: Synonyms: Chemical Family: BeneFIX Recombinant Coagulation Factor IX; nonacog alfa Recombinant protein

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as blood clotting agent

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

#### 2. HAZARDS IDENTIFICATION

# **Classification of the Substance or Mixture**

**GHS - Classification** 

Skin Sensitization: Category 1

#### **US OSHA Specific - Classification**

Physical Hazard: Combustible Dust

#### Label Elements

Signal Word: Hazard Statements:	Warning H317 - May cause an allergic skin reaction May form combustible dust concentrations in air
Precautionary Statements:	<ul> <li>P261 - Avoid breathing dust/fume/gas/mist/vapors/spray</li> <li>P272 - Contaminated work clothing must not be allowed out of the workplace</li> <li>P280 - Wear protective gloves/protective clothing/eye protection/face protection</li> <li>P302+ P352 - IF ON SKIN: Wash with plenty of soap and water</li> <li>P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention</li> <li>P321 - Specific treatment (see supplemental first aid instructions on this label)</li> <li>P363 - Wash contaminated clothing before reuse</li> <li>P501 - Dispose of contents/container in accordance with all local and national regulations</li> </ul>

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887



**Other Hazards** 

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU	GHS Classification	%
		EINECS/ELINCS		
		List		
Glycine	56-40-6	200-272-2	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*
L-Histidine	71-00-1	200-745-3	Not Listed	*
Coagulation Factor IX	9001-28-9	232-594-4	Skin Sens. 1,H317	250-1000 IU/vial

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Polysorbate 80	9005-65-6	Not Listed	Not Listed	*

**Additional Information:** 

#### \* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

#### For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES	
Description of First Aid Measures Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

Material Name: BeneFIX
Revision date: 27-Nov-2016

Symptoms and Effects of	For information on potential signs and symptoms of exposure, See Section 2 - Hazards
Exposure:	Identification and/or Section 11 - Toxicological Information.
Medical Conditions	None known
Aggravated by Exposure:	

#### Indication of the Immediate Medical Attention and Special Treatment Needed Notes to Physician: None

#### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

Hazardous Combustion	Formation of toxic gases is possible during heating or fire.
Products:	

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

#### **Advice for Fire-Fighters**

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES	

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

#### 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

#### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical drug product

#### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

#### Glycine

8. EXPOSURE CONTROLS /	PERSONAL PROTECTION	
Latvia OEL - TWA	5 mg/m <sup>3</sup>	
Sucrose		
ACGIH Threshold Limit Value	e (TWA) 10 mg/m <sup>3</sup>	
Australia TWA	10 mg/m <sup>3</sup>	
Belgium OEL - TWA	10 mg/m <sup>3</sup>	
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>	
Estonia OEL - TWA	10 mg/m <sup>3</sup>	
France OEL - TWA	10 mg/m <sup>3</sup>	
Ireland OEL - TWAs	10 mg/m <sup>3</sup>	
Latvia OEL - TWA	5 mg/m <sup>3</sup>	
Lithuania OEL - TWA	10 mg/m <sup>3</sup>	
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>	
Portugal OEL - TWA	10 mg/m <sup>3</sup>	
Slovakia OEL - TWA	6 mg/m <sup>3</sup>	
Spain OEL - TWA	10 mg/m <sup>3</sup>	
L-Histidine		
Latvia OEL - TWA	5 mg/m <sup>3</sup>	
Exposure Controls		
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General	
	room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne	
	contamination levels below the exposure limits listed above in this section.	
Personal Protective	Refer to applicable national standards and regulations in the selection and use of personal	
Equipment:	protective equipment (PPE). Contact your safety and health professional or safety equipment	
	supplier for assistance in selecting the correct protective clothing/equipment based on an	
	assessment of the workplace conditions, other chemicals used or present in the workplace and	
	specific operational processes.	
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is	
	possible and for bulk processing operations. (Protective gloves must meet the standards in	
	accordance with EN374, ASTM F1001 or international equivalent.)	
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the	
	standards in accordance with EN166, ANSI Z87.1 or international equivalent.)	
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible an	
	for bulk processing operations. (Protective clothing must meet the standards in accordance	
	with EN13982, ANSI 103 or international equivalent.)	
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposure	
	to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must	
	meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international	
	equivalent.)	
	- 1	

# 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	White to almost white
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C):	No data available No data available No data available. No data available		

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available. Partition Coefficient: (Method, pH, Endpoint, Value) Polysorbate 80 No data available **Coagulation Factor IX** No data available Sucrose No data available L-Histidine No data available Glvcine No data available Decomposition Temperature (°C): No data available. Evaporation Rate (Gram/s): No data available Vapor Pressure (kPa): No data available Vapor Density (g/ml): No data available **Relative Density:** No data available No data available Viscosity: Flammablity: No data available Autoignition Temperature (Solid) (°C): Flammability (Solids): No data available Flash Point (Liquid) (°C): No data available

#### **10. STABILITY AND REACTIVITY**

Upper Explosive Limits (Liquid) (% by Vol.):

Lower Explosive Limits (Liquid) (% by Vol.):

Reactivity: Chemical Stability: Possibility of Hazardous Reactions	No data available Stable under normal conditions of use.
Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition Products:	No data available Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers No data available

#### 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	May cause allergic reaction . Pharmaceutical blood clotting agent: may be fatal if injected or enters bloodstream
Known Clinical Effects:	This product contains protein of bovine origin. Those with known sensitivity should avoid contact. Serious allergic reactions, including anaphylaxis, have been reported. Extensive intravascular clotting and death may result if injected or allowed to enter large blood vessels.

No data available

No data available

#### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Polysorbate 80**

#### Material Name: BeneFIX Revision date: 27-Nov-2016

**11. TOXICOLOGICAL INFORMATION** 

Rat Oral LD50 25 g/kg		
Coagulation Factor IX Mouse IP LD50 1000 ug/kg		
Sucrose Rat Oral LD50 29.7 g/kg		
L-Histidine         Rat       Oral       LD 50       > 15 g/kg         Rat       Para-periosteal       LD 50       > 2g/kg         Mouse       Oral       LD 50       > 15g/kg         Mouse       Intravenous       LD 50       > 2g/kg         Acute Toxicity Comments:       A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.		
Genetic Toxicity: (Study Type, Cell Type/Organism, Result)		
Sucrose Bacterial Mutagenicity (Ames) Salmonella Negative		
<b>Carcinogen Status:</b> None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.		
12. ECOLOGICAL INFORMATION		

Environmental Overview:	Environmental properties have not been investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

# **13. DISPOSAL CONSIDERATIONS**

# Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State<br/>specific and Community specific provisions must be considered. Considering the relevant<br/>known environmental and human health hazards of the material, review and implement<br/>appropriate technical and procedural waste water and waste disposal measures to prevent<br/>occupational exposure and environmental release. It is recommended that waste minimization<br/>be practiced. The best available technology should be utilized to prevent environmental<br/>releases. This may include destructive techniques for waste and wastewater.

#### **14. TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

# **15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Glycine

CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 200-272-2
Polysorbate 80	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present Not Listed
Sucrose	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): REACH - Annex IV - Exemptions from the obligations of Register: EU EINECS/ELINCS List	Not Listed Not Listed Present Present Present 200-334-9
L-Histidine	
CERCLA/SARA 313 Emission reporting California Proposition 65 Inventory - United States TSCA - Sect. 8(b) Australia (AICS): EU EINECS/ELINCS List	Not Listed Not Listed Present Present 200-745-3
Coagulation Factor IX CERCLA/SARA 313 Emission reporting California Proposition 65 EU EINECS/ELINCS List	Not Listed Not Listed 232-594-4

# **15. REGULATORY INFORMATION**

# **16. OTHER INFORMATION**

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date:	27-Nov-2016 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

#### End of Safety Data Sheet